Back
SENSE registry for status epilepticus.
Journal article

SENSE registry for status epilepticus.

  • Kellinghaus C Department of Neurology, Klinikum Osnabrück, Osnabrück, Germany.
  • Rossetti AO Department of Clinical Neurosciences, CHUV and University of Lausanne, Lausanne, Switzerland.
  • Trinka E Department of Neurology, Christian Doppler Klinik of Paracelsus Medical University, Salzburg, Austria.
  • Lang N Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Unterberger I Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
  • Rüegg S Department of Neurology, University Hospital Basel, Basel, Switzerland.
  • Tilz C Department of Neurology, Krankenhaus Barmherzige Brüder, Regensburg, Germany.
  • Uzelac Z Department of Neurology, University Hospital Ulm, Ulm, Germany.
  • Rosenow F Department of Neurology, Epilepsy Center Hessen - Marburg, University Hospitals and Philipps-University Marburg, Marburg, Germany.
Show more…
  • 2018-08-31
Published in:
  • Epilepsia. - 2018
registry
status epilepticus
therapy
Adolescent
Adult
Aged
Aged, 80 and over
Anticonvulsants
Austria
Cohort Studies
Female
Germany
Humans
Male
Middle Aged
Registries
Status Epilepticus
Time Factors
Young Adult
English Evidence is scarce regarding the treatment of status epilepticus (SE). Only a few large randomized controlled trials have been published. Therefore, we set up a multicenter registry to prospectively document treatment practice in several different large hospitals in German-speaking countries. Over a period of more than 4 years, we were able to document 1179 episodes of 1049 patients who were treated for SE in 1 of the 8 participating centers in Germany, Austria, and Switzerland. Median age was 70 years. The most frequent etiology was remote (32%), followed by acute (31%), or a mixture of acute and remote factors (10%). Semiology was generalized convulsive in 44%, focal motor in 27%, and nonconvulsive in 30%. Only a few patients did not have relevant comorbidities. Median latency between SE onset and first treatment was 1 hour (median). Three hundred ninety-three (32%) of the patients were treated within 30 minutes after onset. The first treatment step consisted of benzodiazepines in more than 80%, and in levetiracetam in 15%. Five hundred eleven patients (49%) were refractory (defined as ongoing SE after application of benzodiazepine and 1 intravenous anticonvulsant). Further analysis of these registry data may be important for hypothesis generation and trial design for treatment of status epilepticus.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/92796
Statistics
Document views: 28 File downloads: